Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.97 +0.09 (+0.24%)
Official Closing Price Updated: 7:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
35 36 Next >
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029
Via Benzinga
Watch For Continued Gains In Shares Of GlaxoSmithKline PLC (GSK)
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Highly Rated GlaxoSmithKline Eyes Breakout After Racking Up Series Of Wins
The move comes after the FDA shut down its Vir-partnered Covid antibody, however. 
Via Investor's Business Daily
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
Via Investor Brand Network
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
Via Investor Brand Network
Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here
Via Benzinga
What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates?
Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier. 
Via Benzinga
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
From GSK
Via Business Wire
Good and Bad stock news
Microsoft is down because of an FTC investigation of its possible anti-competitive moves. 
Via Talk Markets
CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial
Via Benzinga
LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact
Via Benzinga
EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine
Via Benzinga
Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility
Vir Biotechnology remains under pressure despite its looming addition to a new index. 
Via Investor's Business Daily
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Omicron BA.2 Variant Represents More Than 50% COVID-19 Cases, Says CDC Estimates: WSJ
According to the Centers for Disease Control and Prevention estimates, the omicron BA.2 variant represents approximately 55% of new COVID-19 cases in the U.S., as signs suggest infections are edging... 
Via Benzinga
FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV
Via Benzinga
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country 
Via Benzinga
Monday Markets News
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
Via Benzinga
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. 
Via InvestorPlace
Drug makers, Scientists Working For Long COVID Treatments: Reuters
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,  
Via Benzinga
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher. 
Via Investor's Business Daily
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection. 
Via Benzinga
Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock. The Moderna Analyst: BofA... 
Via Benzinga
Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC
U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases. 
Via Benzinga
WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC
The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren& 
Via Benzinga
News-Filled Day
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC. 
Via Talk Markets
Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial
IDEAYA Biosciences Inc (NASDAQ: IDYA) has announced  
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.